Brief: Coya Therapeutics, Inc. Announces Preclinical Data Supporting The Role Of Expanded Regulatory T Cells (Tregs) As Potential Disease-Modifying Treatment In An Animal Model Of Alzheimer’S Disease (Ad)
26/01/2023 14:05
Jan 26 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS, INC. ANNOUNCES PRECLINICAL DATA
SUPPORTING
THE ROLE OF EXPANDED REGULATORY T CELLS (TREGS) AS POTENTIAL
DISEASE-MODIFYING TREATMENT IN AN ANIMAL MODEL OF ALZHEIMER’S
DISEASE (AD)
* COYA THERAPEUTICS INC- INITIATION OF PHASE I CLINICAL
TRIALS FOR
TREG ENHANCING BIOLOGICS IN NEURODEGENERATIVE DISEASES EXPECTED
IN 2023
* COYA THERAPEUTICS- DATA PROVIDE PRECLINICAL SUPPORT FOR
TREG
ENHANCING THERAPIES AS POTENTIAL TREATMENT STRATEGY IN AD, OTHER
NEURODEGENERATIVE DISEASES
Source text for Eikon: ID:nBwc0CNh3a
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)